RESUMEN
OBJECTIVE: Pancreatic enzyme is essential in the treatment of cystic fibrosis (CF), but intolerance to it occasionally occurs. We encountered a child who was intolerant to multiple commercially available preparations of pancreatic enzymes and, hence, desensitization was attempted, with success. CASE PRESENTATION: A 33-month-old girl was diagnosed with CF at 6 months of age. Initially, she was started on Pancrease MT 16, which was subsequently discontinued because fecal fat studies were normal and she seemed to do well on Nutramigen and vitamin supplements. At 29 months of age, she developed diarrhea with bulky stools and weight loss. A fecal fat 72-hour study revealed a coefficient of absorption of 50%. She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes. The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. Vomiting occurred even with small doses of enzymes disguised in food. She had no history suggestive of gastroesophageal reflux, peptic ulcer, or pork allergy, and no vomiting on days when enzymes were not given. This was suggestive of type I hypersensitivity reaction. Pancreatic enzymes were discontinued, and she was given a low-fat, high-carbohydrate diet with satisfactory weight gain. METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo. Rush oral desensitization with Viokase solution was attempted, starting with 5 mg, and the dose was doubled every 20 minutes, aiming to reach a cumulative dose of 700 mg. However, the child vomited when a cumulative dose of 315 mg was reached. Another trial of slower desensitization was done using Pancrease MT 16 (1 capsule: 16 000 U of lipase, 48 000 U of amylase, and 48 000 U of protease), starting with 1/4 capsule per day, with increments of 1/4 capsule every 3 days, until an entire capsule was reached by day 10, then increased by approximately 1/2 capsule every 4 days until reaching the therapeutic dose of 1 capsule with each meal by day 25. RESULTS: The patient tolerated this fairly well and has been on this treatment and regular diet for >1 year, without any adverse reaction. This illustrates a rare case of gastrointestinal adverse reaction to pancreatic enzymes that was treated successfully with desensitization. CONCLUSION: Pancreatic enzyme intolerance, although rare, would be a major problem in the management of patients with CF. Hence, desensitization would be essential and may be accomplished successfully using the protocol described in this report.
Asunto(s)
Fibrosis Quística/tratamiento farmacológico , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/terapia , Extractos Pancreáticos/efectos adversos , Preescolar , Diarrea/inducido químicamente , Método Doble Ciego , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a las Drogas/inmunología , Femenino , Humanos , Extractos Pancreáticos/uso terapéutico , Pérdida de PesoRESUMEN
Colonic strictures are rare in patients who have cystic fibrosis, but recently have developed in those who have been treated with delayed-release high-dose pancreatic enzyme supplements. Colonic strictures from eight such pediatric patients showed neural abnormalities consisting of ganglion cell hyperplasia and ectopia, and intermyenteric plexus hyperplasia. Cholinergic and adrenergic stains of mucosal nerve fibers were more prominent in histological sections of the cystic fibrosis strictures than in sections from colons of children without cystic fibrosis. The mean grade of staining with acetylcholinesterase in the lamina propria of the strictured cystic fibrosis colons was 2.38 +/- 1.25, compared with .93 +/- .93 (P < .055) in bowels from children without cystic fibrosis. The mean grade for tyrosine hydroxylase staining in the lamina propria was 2 +/- .97 in the strictures and was .79 +/- .81 (P < .05) in the bowels of children who did not have cystic fibrosis. Vasoactive intestinal peptide staining in bowels from children with cystic fibrosis with and without stricture did not differ significantly from that of children without cystic fibrosis. Vasculopathy consisting of fibrointimal hyperplasia in submucosal veins and mesenteric arteries was found only in colonic strictures owing to cystic fibrosis. Colonic strictures in patients with cystic fibrosis who received high-dose pancreatic enzyme supplements contain ganglion cell abnormalities, and mucosal cholinergic and adrenergic activity may be increased in these strictures. The stricture vasculopathy may be drug-related and/or related to increased catecholamine activity.
Asunto(s)
Enfermedades del Colon/patología , Fibrosis Quística/patología , Páncreas/enzimología , Acetilcolinesterasa/análisis , Adolescente , Fibras Adrenérgicas/patología , Catecolaminas/análisis , Niño , Preescolar , Fibras Colinérgicas/patología , Coristoma/patología , Colon/irrigación sanguínea , Colon/inervación , Colon/patología , Enfermedades del Colon/inducido químicamente , Constricción Patológica/inducido químicamente , Constricción Patológica/patología , Fibrosis Quística/tratamiento farmacológico , Femenino , Ganglios/patología , Humanos , Hiperplasia , Recién Nacido , Mucosa Intestinal/irrigación sanguínea , Mucosa Intestinal/inervación , Mucosa Intestinal/patología , Masculino , Arterias Mesentéricas/patología , Extractos Pancreáticos/efectos adversos , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/patología , Túnica Íntima/patología , Tirosina 3-Monooxigenasa/análisis , Enfermedades Vasculares/inducido químicamente , Enfermedades Vasculares/patología , Péptido Intestinal Vasoactivo/análisisRESUMEN
Fibrosing colonopathy was first described in cystic fibrosis (CF) children in 1994. We have done a nested case-control study to identify possible associations with this condition. A case ascertainment within the UK CF population to identify any cases that occurred between January, 1984, and April, 1994, found 14 cases, all under 14 years and confirmed by independent histopathological review. All had presented since April, 1993; 12 were boys and six had received some or all of their care in Liverpool. Each case was matched, by date of birth, with four controls from the UK CF Registry. Information was obtained about cases and controls from their case records and by a structured interview with the families. In the 12 months before surgery, there was an association between the occurrence of fibrosing colonopathy and use of high-strength pancreatic enzyme preparations. This association was dose related. Odds ratio per extra 1000 high-strength capsules was 1.45 (95% CI 1.14-1.84). For use of protease, the odds ratio per million extra units per kg was 1.55 (1.19-2.03). For usage of individual high-strength products at any time during the 12 months before surgery some differences were observed; for Creon 25000 the odds ratio was 0.38 (0.10-1.42), for Nutrizym 22 43.4 (2.51-751), and for Pancrease HL 8.4 (1.95-36.1). These last two confidence intervals are extremely wide and compatible with these two products having the same odds ratios. Laxative use was independently predictive (odds ratio 2.42 [1.20-4.94]). We conclude that there is a dose-related association between high-strength pancreatic enzyme preparations and fibrosing colonopathy.
Asunto(s)
Enfermedades del Colon/epidemiología , Fibrosis Quística/epidemiología , Adolescente , Amilasas/administración & dosificación , Amilasas/efectos adversos , Bromelaínas/administración & dosificación , Bromelaínas/efectos adversos , Estudios de Casos y Controles , Catárticos/efectos adversos , Catárticos/uso terapéutico , Niño , Preescolar , Estudios de Cohortes , Enfermedades del Colon/cirugía , Intervalos de Confianza , Constricción Patológica/epidemiología , Constricción Patológica/cirugía , Fibrosis Quística/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Femenino , Fibrosis , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/efectos adversos , Humanos , Lipasa/administración & dosificación , Lipasa/efectos adversos , Masculino , Oportunidad Relativa , Extractos Pancreáticos/administración & dosificación , Extractos Pancreáticos/efectos adversos , Pancreatina/administración & dosificación , Pancreatina/efectos adversos , Pancrelipasa , Sistema de Registros , Factores de Riesgo , Tripsina/administración & dosificación , Tripsina/efectos adversos , Reino Unido/epidemiologíaRESUMEN
We used a whole-gut perfusion technique to study subclinical gut inflammation in children with cystic fibrosis (18 elective tests, three lavages to treat distal intestinal obstruction syndrome); and in 12 control children with constipation or pre-colonoscopy. We assayed for haemoglobin, IgG, albumin, alpha-1-antitrypsin, granulocyte elastase, interleukin-1 beta (IL-1 beta) and IL-8 concentrations in whole-gut lavage fluid. Results for two children with distal intestinal obstruction syndrome, the only children in the series taking Nutrizym 22, were strikingly abnormal. This new test has revealed subclinical gut mucosal inflammation in a minority of CF children, for which distal intestinal obstruction syndrome, Nutrizym 22 treatment, or both, may be risk factors.
Asunto(s)
Amilasas/efectos adversos , Bromelaínas/efectos adversos , Colitis/inducido químicamente , Fibrosis Quística/tratamiento farmacológico , Fármacos Gastrointestinales/efectos adversos , Lipasa/efectos adversos , Extractos Pancreáticos/efectos adversos , Pancreatina/efectos adversos , Tripsina/efectos adversos , Adolescente , Albúminas/análisis , Amilasas/administración & dosificación , Bromelaínas/administración & dosificación , Estudios de Casos y Controles , Niño , Preescolar , Colitis/metabolismo , Colonoscopía , Estreñimiento/metabolismo , Combinación de Medicamentos , Femenino , Fármacos Gastrointestinales/administración & dosificación , Hemoglobinas/análisis , Humanos , Inmunoglobulina G/análisis , Interleucina-1/análisis , Interleucina-8/análisis , Obstrucción Intestinal/inducido químicamente , Obstrucción Intestinal/metabolismo , Elastasa de Leucocito , Lipasa/administración & dosificación , Masculino , Elastasa Pancreática/análisis , Pancreatina/administración & dosificación , Pancrelipasa , Factores de Riesgo , Síndrome , Irrigación Terapéutica , Tripsina/administración & dosificación , alfa 1-Antitripsina/análisisRESUMEN
A 2 1/2-year-old girl with cystic fibrosis, who presented with hematochezia, developed an inflammatory ulcerative type of colitis with mild interstitial fibrosis and colonic narrowing while being treated with high strength pancreatic enzyme supplements. Findings of contrast enema, endoscopy, and colonic biopsy are described. The spectrum of colonic disease associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis patients is discussed.
Asunto(s)
Colitis Ulcerosa/inducido químicamente , Fibrosis Quística/tratamiento farmacológico , Extractos Pancreáticos/efectos adversos , Preescolar , Colitis Ulcerosa/patología , Colon/patología , Constricción Patológica/inducido químicamente , Constricción Patológica/patología , Femenino , Fibrosis , Hemorragia Gastrointestinal/inducido químicamente , Humanos , Extractos Pancreáticos/administración & dosificación , Extractos Pancreáticos/uso terapéuticoRESUMEN
Iron deficiency has been reported in one third of patients with cystic fibrosis. There are data that suggest that iron absorption is increased with exocrine pancreatic deficiency and that administration of pancreatic enzymes may impair oral iron absorption. We compared oral iron absorption over a 3-hour period in the presence and absence of exogenous pancreatic enzymes in 13 stable young-adult patients with cystic fibrosis and 9 age-matched control patients. Although none of the patients with cystic fibrosis had a hemoglobin level less than 119 g/L, serum ferritin levels were less than 25 micrograms/L in 5 of the 13 patients, and the mean corpuscular volume was significantly lower in the patient group (86.1 +/- 2.7 vs 90.9 +/- 5 fL). Baseline mean serum iron levels were higher in controls (18.9 +/- 5.9 mumol/L) than in patients (11.9 +/- 6.3 mumol/L). There was no difference in iron absorption in the absence of exogenous pancreatic enzymes. Significant impairment of iron absorption was detected in both patients with cystic fibrosis and controls after administration of a preparation of pancreatic enzymes. There was an inverse relationship between iron stores, as measured by serum ferritin, and iron absorption. These findings suggest that long-term consumption of pancreatic enzymes by patients with cystic fibrosis may contribute to iron deficiency.
Asunto(s)
Hierro/farmacocinética , Lipasa/efectos adversos , Extractos Pancreáticos/efectos adversos , Adolescente , Adulto , Fibrosis Quística/tratamiento farmacológico , Femenino , Ferritinas/sangre , Humanos , Hierro/sangre , Deficiencias de Hierro , Masculino , PancrelipasaRESUMEN
Dysuria, uric acid crystalluria and hyperuricosuria developed in a child with cystic fibrosis and normal serum uric acid. Hyperuricosuria in this patient and two other children was directly related to ingestion of large amounts of pancreatic extract. In these three children, reducing pancreatic extract dosage by 85 percent lowered their purine intake by 307, 225, and 148 mg, respectively; urinary uric acid excretion decreased by 245, 239, and 158 mg. Overmedication resulted from parents' decisions to increase enzyme dosages. In our cystic fibrosis clinic, 15 of 32 patients screened at random were taking higher than the prescribed dose of pancreatic enzymes, and 14 of these 15 children were hyperuricosuric. On the basis of this information, we suggest that the minimal effective dose of pancreatic extract should be determined and adhered to for each child with cystic fibrosis to avoid potential renal injury from hyperuricosuria.